Primary Objective:

To investigate effects of SAR440340 (anti-interleukin-33 [IL?33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.